Allergan's Migraine Leadership Recognized with Enrico Greppi Award for Excellence in Headache Research

    Allergan's Migraine Leadership Recognized with Enrico Greppi Award for
                       Excellence in Headache Research

Allergan to present award-winning study and six additional presentations at
the 11th European Headache Federation Congress

PR Newswire

DUBLIN, Nov. 29, 2017

DUBLIN, Nov. 29, 2017 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading
global pharmaceutical company, is pleased to announce that its manuscript,
"Fluctuations in Episodic and Chronic Migraine Status Over the Course of One
Year: Implications for Diagnosis, Treatment and Clinical Trial Design," has
been selected as the 2017 Enrico Greppi Award Winner. The Italian Society for
the Study of Headaches (SISC) grants the annual Award to the best unpublished
original paper dealing with clinical, epidemiological, genetic,
pathophysiological or therapeutic aspects of headache, in memory of Enrico
Greppi, a pioneer and expert in the study of headache.

Allergan plc logo

"We are honored to receive this prestigious award and the recognition of the
importance of gaining a data-driven understanding of chronic migraine to
improve classification, diagnosis and clinical trial design," says Richard
Lipton, MD, Vice Chair of Neurology, Albert Einstein College of Medicine, and
an author on the paper. "There is a traditional bright line of 15 headache
days that separates people with episodic migraine from those with chronic
migraine, but people with migraine experience striking fluctuations in the
frequency of their headache attacks. Therefore, days alone may not be
sufficiently stable to distinguish between episodic and chronic migraine. More
data is needed to fully understand the underlying biological differences."

The award-winning manuscript, which was published in The Journal of Headache
and Pain and will be presented at the 11th European Headache Federation (EHF)
Congress in Rome, includes findings from the longitudinal Chronic Migraine
Epidemiology and Outcomes (CaMEO) Study, which recruited nearly 17,000
individuals with migraine from a web-based panel, to complete a series of
surveys for more than one year. It was purposely designed to characterize
natural migraine disease course; quantify its societal, familial, and economic
impact; and provide an evidence-based foundation to improve migraine care.

"For decades, Allergan has been investing in research that continues to
uncover new data about headache medicine and improve our understanding of the
disease. We're proud to be recognized with this prestigious award and share
our latest data on a global stage," said David Nicholson, Chief Research &
Development Officer at Allergan. "We congratulate the authors on this honor
and are grateful for their shared commitment to the future of headache

Allergan will also present six additional abstracts on Chronic Migraine and
the Company's Chronic Migraine treatment. Beyond the award lecture, highlights
include three podium presentations on findings from the CaMEO study on
comorbidities of migraine, the REPOSE study on the safety and effectiveness of
BOTOX^® (onabotulinumtoxinA) for the treatment of Chronic Migraine, and the
FORWARD study comparing the tolerability profile of BOTOX^® and topiramate for
the preventive treatment of Chronic Migraine. Allergan will also present four
posters containing data from CaMEO and FORWARD studies, and the diagnosis of
patients with Chronic Migraine.

The following presentations will take place at the 11th European Headache
Federation (EHF) Congress in Rome from December 1-3, 2017:

  o Fluctuations in Episodic Chronic Migraine Status Over the Course of One
    Year: Implications for Diagnosis, Treatment, and Clinical Trial Design
    (Greppi Award Winner). Authors: Serrano D, et al [Oral Presentation]
  o The Relationship Between Pain, Psychiatric, and Endocrine/Neurological
    Comorbidities of Migraine: Results from the Chronic Migraine Epidemiology
    and Outcomes (CaMEO) Study. Authors: Lipton RB, et al. [Oral Presentation]
  o Real-life Use of OnabotulinumtoxinA for the Symptomatic Treatment of
    Chronic Migraine: The REPOSE Study. Authors: Ahmed F, et al. [Oral
  o A Multicenter, Prospective, Randomized, Open-label Study to Compare the
    Efficacy, Safety, and Tolerability of OnabotulinumtoxinA and Topiramate
    for Headache Prophylaxis in Adults with Chronic Migraine: The FORWARD
    Study. Authors: Rothrock JF, et al. [Oral Presentation & E-Poster]
  o The Relationship Between Sleep Disorders and Migraine: Results from the
    Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Authors: Buse
    DC, et al. [E-Poster]
  o Medical (Respiratory, Sleep, Cardiovascular and Gastrointestinal)
    Comorbidities of Migraine: Results from the Chronic Migraine Epidemiology
    and Outcomes (CaMEO) Study. Authors: Lipton RB, et al. [E-Poster]
  o Development of a Claims-based Algorithm for Use in Patients with Migraine
    to Identify Potentially Undiagnosed Chronic Migraine Patients. Authors:
    Pavlovic JM, et al. [E-Poster]

Allergan, a leader in the Chronic Migraine space, markets BOTOX^®
(onabotulinumtoxinA) the first and only FDA-approved, preventive treatment for
adult Chronic Migraine patients since it was approved in 2010. Allergan is
also advancing its migraine program with two investigational small molecule
oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are
being developed for the treatment and prevention of migraine. Allergan's
CGRPs, ubrogepant in Phase III for the acute treatment of migraine and
atogepant in Phase II for the prevention of migraine, are expected to be the
first oral CGRP receptor antagonists to market.

Funding for the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study was
provided by Allergan plc.

Allergan's Commitment to People with Migraine

Allergan is committed to advancing the science of migraine through ongoing
research and clinical investment, while providing innovative treatment
approaches, educational opportunities, and support services that improve the
lives of patients. Allergan tirelessly pursues freedom from migraine in
partnership with the entire migraine community.

BOTOX^® (onabotulinumtoxinA) Important Information


BOTOX^® is a prescription medicine that is injected to prevent headaches in
adults with chronic migraine who have 15 or more days each month with headache
lasting 4 or more hours each day in people 18 years or older.

It is not known whether BOTOX^® is safe or effective to prevent headaches in
patients with migraine who have 14 or fewer headache days each month (episodic


BOTOX^® may cause serious side effects that can be life threatening. Get
medical help right away if you have any of these problems any time (hours to
weeks) after injection of BOTOX^®:

  o Problems swallowing, speaking, or breathing, due to weakening
    of associated muscles, can be severe and result in loss of life. You are
    at the highest risk if these problems are pre-existing before injection.
    Swallowing problems may last for several months.
  o Spread of toxin effects. The effect of botulinum toxin may affect areas
    away from the injection site and cause serious symptoms including: loss of
    strength and all-over muscle weakness, double vision, blurred vision and
    drooping eyelids, hoarseness or change or loss of voice, trouble saying
    words clearly, loss of bladder control, trouble breathing, trouble

There has not been a confirmed serious case of spread of toxin effect away
from the injection site when BOTOX^® has been used at the recommended dose to
treat chronic migraine.

BOTOX^® may cause loss of strength or general muscle weakness, vision
problems, or dizziness within hours to weeks of taking BOTOX^®.  If this
happens, do not drive a car, operate machinery, or do other dangerous

Do not receive BOTOX^® if you: are allergic to any of the ingredients in
BOTOX^®; had an allergic reaction to any other botulinum toxin product; have a
skin infection at the planned injection site. Serious and/or immediate
allergic reactions have been reported. Get medical help right away if you
experience symptoms; further injection of BOTOX^® should be discontinued. Tell
your doctor about all your muscle, nerve and medical conditions. Tell your
doctor about all the medicines you take. Using BOTOX^® with certain other
medicines may cause serious side effects. The most common side effects include
neck pain and headache.

For more information, refer to the Medication Guide or talk with your doctor.
You are encouraged to report negative side effects of prescription drugs to
the FDA. Visit or call 1-800-FDA-1088.

Please see BOTOX^® full Product Information including Boxed Warning and
Medication Guide.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model – Growth
Pharma. Allergan is focused on developing, manufacturing and commercializing
branded pharmaceutical, device, biologic, surgical and regenerative medicine
products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for
the central nervous system, eye care, medical aesthetics and dermatology,
gastroenterology, women's health, urology and anti-infective therapeutic

Allergan is an industry leader in Open Science, a model of research and
development, which defines our approach to identifying and developing
game-changing ideas and innovation for better patient care. With this
approach, Allergan has built one of the broadest development pipelines in the
pharmaceutical industry with 55+ mid-to-late stage pipeline programs currently
in development.

Allergan's success is powered by our more than 18,000 global colleagues'
commitment to being Bold for Life. Together, we build bridges, power ideas,
act fast and drive results for our customers and patients around the world by
always doing what is right.

With commercial operations in approximately 100 countries, Allergan is
committed to working with physicians, healthcare providers and patients to
deliver innovative and meaningful treatments that help people around the world
live longer, healthier lives every day.

For more information, visit Allergan's website at

Forward-Looking Statement

Statements contained in this press release that refer to future events or
other non-historical facts are forward-looking statements that reflect
Allergan's current perspective on existing trends and information as of the
date of this release. Actual results may differ materially from Allergan's
current expectations depending upon a number of factors affecting Allergan's
business. These factors include, among others, the difficulty of predicting
the timing or outcome of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and continued demand
for Allergan's products; the impact of uncertainty around timing of generic
entry related to key products, including RESTASIS^®, on our financial results;
uncertainty associated with financial projections, projected cost reductions,
projected synergies, restructurings, increased costs, and adverse tax
consequences; difficulties or delays in manufacturing; and other risks and
uncertainties detailed in Allergan's periodic public filings with the
Securities and Exchange Commission, including but not limited to Allergan's
Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's
Quarterly Report on Form 10-Q for the period ended September 30, 2017. Except
as expressly required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements.



Daphne Karydas
(862) 261-8006

Mark Marmur
(862) 261-7558

View original content with

SOURCE Allergan plc

Press spacebar to pause and continue. Press esc to stop.